References
- Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Clinical Practice Guideline Number 9. Rockville, Md: AHCPR Publication, 1994, pp 1–257
- Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000;38:59–89
- Makin MK. Strong opioids for cancer pain. J R Soc Med 2001;94:17–21
- Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer 1987;59:850–6
- Vielvoye-Kerkmeer AP, Mattern C, Uitendaal MP. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage 2000;19:185–92
- Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000;14:111–19
- Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997;13:254–61
- Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588–93
- Donner B, Zenz M, Strumpf M, et al. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998;15:168–75
- Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other disease. Pain 1983;17:197–210
- Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–5
- Turk DC, Rudy TE: IASP taxonomy of chronic pain syndromes: preliminary assessment of reliability. Pain 1987;30:177–89
- Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527–34
- Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154–8
- Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer Drugs 1995;6(Suppl 3):39–43
- Southam MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anticancer Drugs 1995;6(Suppl 3):29–34
- Korte W. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: Short-and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 1996;11:139–46
- Mercadante S, Fulfaro F: Alternatives to oral opioids for cancer pain. Oncology 1999;13:215–25
- Zech DFJ, Grond SUA, Lynch J, et al. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992;50:293–301
- Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997;53:109–38
- Cleary JF. Cancer pain management. Cancer Control 2000;7:120–31
- Yeo W, Lam KK, Chan AT, Leung TW, Nip SY, Johnson PJ. Transdermal fentanyl for severe cancer-related pain. Palliat Med 1997;11:233–9
- Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997;69:191–8
- Menten J, Desmedt M, Lossignol D, Mullie A. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: Results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin 2003;18:488–98